Medical

Aurorix

moclobemide

A reversible mono-amine oxidase inhibitor (MAOI) used to manage depression and performance anxiety. It is not approved for use in the USA.
 
Adverse effects
Insomnia, headache, dizziness.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

Aurorix®

Moclobemide, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in
References in periodicals archive
The EUR120m transaction, initially announced in August, covers world-wide rights to Marcoumar, Torem, Tilcotil and Aurorix, which together represent annual sales of some SEK500m.
Meda AB completes acquisition of product portfolio from Roche
Top-Selling Antidepressant Pharmaceuticals 1998 Sales in Billions Prozac $2,812.00 Zoloft $1,836.00 Paxil $1,757.00 Effexor $529.00 Wellbutrin $508.79 Serzone $257.00 Remeron $178.45 Aurorix $96.51 Tolvon $71.08 Elen $70.23 Source: MedAd News
New, Old Antidepressants Equal in Tolerability, Dropouts
Lurasidone * Latuda Mirtazapine * Remeron Moclobemide * Amira, Aurorix, Clobemix, Depnil, Manerix Modafinil * Provigil Olanzapine/fluoxetine * Symbyax Paroxetine * Paxil Phenelzine * Nardil Pramipexole * Mirapex Quetiapine * Seroquel Riluzole * Rilutek Sertraline * Zoloft Vortioxetine * Brintellix
A practical approach to subtyping depression among your patients: increase treatment success by assessing for the multiple forms that depressive disorders take
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.